JP2017523226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523226A5 JP2017523226A5 JP2017507411A JP2017507411A JP2017523226A5 JP 2017523226 A5 JP2017523226 A5 JP 2017523226A5 JP 2017507411 A JP2017507411 A JP 2017507411A JP 2017507411 A JP2017507411 A JP 2017507411A JP 2017523226 A5 JP2017523226 A5 JP 2017523226A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- groups
- aryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 125000003118 aryl group Chemical group 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000732 arylene group Chemical group 0.000 claims 5
- 125000005549 heteroarylene group Chemical group 0.000 claims 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 125000005551 pyridylene group Chemical group 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000005576 pyrimidinylene group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 206010033307 Overweight Diseases 0.000 claims 2
- 125000002619 bicyclic group Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 1
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 1
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000003003 spiro group Chemical group 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 0 ***c1c(*)cc2[n]c(O*)nc2n1 Chemical compound ***c1c(*)cc2[n]c(O*)nc2n1 0.000 description 2
- XRLYZEPHSWWNRC-UHFFFAOYSA-N C=NN=S1(N(CI)CCC1)=O Chemical compound C=NN=S1(N(CI)CCC1)=O XRLYZEPHSWWNRC-UHFFFAOYSA-N 0.000 description 1
- IKGMIRQEXATIQO-UHFFFAOYSA-N CN(CCC1)S1(=NC)=O Chemical compound CN(CCC1)S1(=NC)=O IKGMIRQEXATIQO-UHFFFAOYSA-N 0.000 description 1
- QRSBORLMJCFWPN-UHFFFAOYSA-N CN=S(CCC1)(N1N)=O Chemical compound CN=S(CCC1)(N1N)=O QRSBORLMJCFWPN-UHFFFAOYSA-N 0.000 description 1
- NVRANQZRQMTEHR-UHFFFAOYSA-N CN=S1(N(CN)CCC1)=O Chemical compound CN=S1(N(CN)CCC1)=O NVRANQZRQMTEHR-UHFFFAOYSA-N 0.000 description 1
- QTDXSEZXAPHVBI-LJGSYFOKSA-N C[C@H](CC1)CC[C@@H]1C(O)=O Chemical compound C[C@H](CC1)CC[C@@H]1C(O)=O QTDXSEZXAPHVBI-LJGSYFOKSA-N 0.000 description 1
- JUHJMRCPZRWQAM-DBRKOABJSA-N C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2O Chemical compound C[C@H](CO[C@@H]12)[C@H]1OC[C@H]2O JUHJMRCPZRWQAM-DBRKOABJSA-N 0.000 description 1
- RKSJJUOPDBHSGU-PBXRRBTRSA-N C[C@H](CO[C@@H]1CO)[C@@H]1O Chemical compound C[C@H](CO[C@@H]1CO)[C@@H]1O RKSJJUOPDBHSGU-PBXRRBTRSA-N 0.000 description 1
- MJUFRKJSBSDWCL-UHFFFAOYSA-N NCN(CCC1)S1(=NN)=O Chemical compound NCN(CCC1)S1(=NN)=O MJUFRKJSBSDWCL-UHFFFAOYSA-N 0.000 description 1
- GBAZJASSZQPDFT-NTSWFWBYSA-N OC[C@H]1OCCC[C@@H]1O Chemical compound OC[C@H]1OCCC[C@@H]1O GBAZJASSZQPDFT-NTSWFWBYSA-N 0.000 description 1
- UBVWYDZEQJSKOY-HSUXUTPPSA-N O[C@H]1[C@H]2OCC[C@H]2OC1 Chemical compound O[C@H]1[C@H]2OCC[C@H]2OC1 UBVWYDZEQJSKOY-HSUXUTPPSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14180549.9 | 2014-08-11 | ||
| EP14180549 | 2014-08-11 | ||
| PCT/EP2015/067900 WO2016023789A1 (en) | 2014-08-11 | 2015-08-04 | Azabenzimidazole derivatives as amp protein kinase agonistes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523226A JP2017523226A (ja) | 2017-08-17 |
| JP2017523226A5 true JP2017523226A5 (enExample) | 2018-09-20 |
| JP6588966B2 JP6588966B2 (ja) | 2019-10-09 |
Family
ID=51298659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507411A Active JP6588966B2 (ja) | 2014-08-11 | 2015-08-04 | Ａｍｐタンパク質キナーゼ作動薬としてのアザベンゾイミダゾール誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US9422312B2 (enExample) |
| EP (1) | EP3180338B1 (enExample) |
| JP (1) | JP6588966B2 (enExample) |
| WO (1) | WO2016023789A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016031842A1 (ja) | 2014-08-27 | 2016-03-03 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有するアザインドール誘導体 |
| WO2016068099A1 (ja) | 2014-10-28 | 2016-05-06 | 塩野義製薬株式会社 | Ａｍｐｋ活性化作用を有する複素環誘導体 |
| CA3014858A1 (en) | 2016-02-26 | 2017-08-31 | Shionogi & Co., Ltd. | 5-phenylazaindole derivative having ampk-activating activity |
| CA3024090A1 (en) * | 2016-05-20 | 2017-11-23 | Shionogi & Co., Ltd. | 5-substituted benzimidazole and 5-substituted azabenzimidazole derivative both having ampk activation effect |
| UY37659A (es) | 2017-04-10 | 2018-10-31 | Phenex Fxr Gmbh | Moduladores del receptor x del hígado (lxr) |
| UY39222A (es) | 2020-05-19 | 2021-11-30 | Kallyope Inc | Activadores de la ampk |
| CN113717087A (zh) * | 2020-05-26 | 2021-11-30 | 瑞博(杭州)医药科技有限公司 | 一种脱氧氟化试剂的制备方法 |
| AU2021297323A1 (en) | 2020-06-26 | 2023-02-16 | Kallyope, Inc. | AMPK activators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2786314A1 (en) * | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2617722B1 (en) * | 2010-09-10 | 2016-03-23 | Shionogi & Co., Ltd. | Hetero ring-fused imidazole derivative having ampk activating effect |
| BR122021002201A8 (pt) * | 2011-02-25 | 2023-04-11 | Merck Sharp & Dohme | Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença |
| US9382243B2 (en) * | 2012-08-22 | 2016-07-05 | Merck Sharp & Dohme Corp. | Azabenzimidazole tetrahydropyran derivatives |
| CN105377857B (zh) * | 2013-07-17 | 2018-04-10 | 勃林格殷格翰国际有限公司 | 新颖氮杂苯并咪唑衍生物 |
-
2015
- 2015-08-04 JP JP2017507411A patent/JP6588966B2/ja active Active
- 2015-08-04 WO PCT/EP2015/067900 patent/WO2016023789A1/en not_active Ceased
- 2015-08-04 EP EP15747465.1A patent/EP3180338B1/en active Active
- 2015-08-10 US US14/822,268 patent/US9422312B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523226A5 (enExample) | ||
| JP2016527223A5 (enExample) | ||
| JP2016508506A5 (enExample) | ||
| JP2015523339A5 (enExample) | ||
| JP2009526761A5 (enExample) | ||
| JP2015511613A5 (enExample) | ||
| JP2011523412A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2018535963A5 (enExample) | ||
| JP2013510124A5 (enExample) | ||
| JP2010523476A5 (enExample) | ||
| JP2018526405A5 (enExample) | ||
| JP2016534084A5 (enExample) | ||
| JP2018526352A5 (enExample) | ||
| JP2011521911A5 (enExample) | ||
| JP2016505637A5 (enExample) | ||
| SI2303270T1 (en) | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceutical products | |
| JP2012533546A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| JP2014518266A5 (enExample) | ||
| JP2018502133A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| JP2017503760A5 (enExample) | ||
| JP2020505400A5 (enExample) |